Oriola
1,07
EUR
-5,31 %
7.705 følger denne virksomhed
OKDBV
NASDAQ Helsinki
Medical Equipment & Services
Health Care
Overview
Finansielt overblik og estimater
Investor consensus
-5,31%
+8,52%
+16,05%
+20,22%
+15,68%
+5,31%
-43,21%
-35,07%
-41,83%
Oriola is a pharmaceutical group with a special focus on the distribution of pharmaceuticals to other companies in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest presence is in the Nordic and Baltic countries. The head office is located in Espoo.
Læs mereMarkedsværdi
194,19 mio. EUR
Aktieomsætning
792,6 t EUR
P/E (adj.) (25e)
16,61
EV/EBIT (adj.) (25e)
4,67
P/B (25e)
1,57
EV/S (25e)
0,06
Udbytteafkast, % (25e)
6,54 %
Omsætning og EBIT-margin
Omsætning mia.
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Finanskalender
3.4
2025
Årligt udbytte
29.4
2025
Delårsrapport Q1'25
18.7
2025
Delårsrapport Q2'25
Risiko
Business risk
Valuation risk
Lav
Høj
Alle
Analyse
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Oriola Oyj: Resolutions of the Annual General Meeting of Oriola Corporation - Combination of share classes and thereto related directed issuance of shares without payment approved
Oriola Oyj: Oriola has completed the sale of Svensk dos AB to Apotekstjänst Sverige AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Oriola Oyj: Oriola's Annual Report 2024 published
Oriola Oyj: Oriola's sale of Svensk dos AB to Apotekstjänst Sverige AB proceeds - sale expected to be completed in Q2 2025
Oriola Q4’24: Write-down weighed on reported earnings
Oriola Oyj: Notice to Oriola Corporation's Annual General Meeting 2025
Oriola, Webcast, Q4'24
Oriola Oyj: Oriola Corporation's Financial Statements Release 1 January-31 December 2024
Oriola Oyj: Oriola's Board of Directors recommends that the shareholder's proposal regarding combination of share classes and directed issuance of shares without payment be accepted at the Annual General Meeting
Oriola Oyj: Oriola appoints Stig Tornell as Executive Vice President, Sales
Oriola Oyj: Oriola Corporation to publish its Financial Statements Release 2024 on 4 March 2025
Oriola Oyj: Oriola Corporation's shareholder's demand for including combination of share classes and directed issuance of shares without payment in the agenda of the Annual General Meeting
Oriola Oyj: Oriola acquires MedInfo ApS in Denmark to strengthen its Nordic footprint in medical information and patient support programmes
Oriola Oyj: Proposals of the Shareholders' Nomination Board of Oriola Corporation concerning the Board of Directors to be elected by the 2025 Annual General Meeting
Oriola Oyj: Oriola to record an impairment of approximately EUR 16 million related to its joint venture Kronans Apotek
Oriola Oyj: Oriola renews operating model and management team to accelerate strategy execution
Oriola Oyj: The Swedish Patent and Market Court rejected Apotekstjänst Sverige AB's appeal regarding the sale of Svensk dos AB
